logo BDSP

Base documentaire


  1. Estrogen replacement therapy after treatment for localized breast carcinoma : Patient responses and opinions.

    Article - En anglais

    BACKGROUND

    Women who reach menopause after receiving treatment for breast carcinoma have been advised to avoid estrogen replacement therapy (ERT), but the validity of this practice is being reappraised and the need for prospective studies is discussed.

    The likely response of potential participants to the tangible rather than theoretic option for ERT provides not only useful information for planning such studies hut also important insights into the attitudes and expectations of breast cancer survivors.

    METHODS

    Women with a history of localized breast carcinoma, potentially eligible for participation in this prospective ERT study, were interviewed in person or by telephone and were asked to consider participation in a prospective, randomized study of ERT.

    In addition, information was obtained regarding their disease stage, estrogen receptor (ER) status, age at diagnosis, age at interview, and elapsed time since cancer treatment.

    RESULTS

    The authors contacted 555 women ; 137 did not meet criteria for study participation.

    Among the 418 women eligible for the program, one-third indicated a lack of interest and cited travel, financial, or age considerations.

    One-third of the women were apprehensive about ERT risk and declined.

    Forty women (13%) were either already receiving ERT or were seeking a prescribing physician.

    Finally, 17% of the women enrolled in our study. (...)

    Mots-clés Pascal : Carcinome, Glande mammaire, Femelle, Homme, Ménopause, Traitement substitutif, Oestrogène, Chimiothérapie, Attitude, Comportement, Evaluation, Questionnaire, Tumeur maligne, Glande mammaire pathologie, Hormone stéroïde sexuelle

    Mots-clés Pascal anglais : Carcinoma, Mammary gland, Female, Human, Menopause, Replacement therapy, Estrogen, Chemotherapy, Attitude, Behavior, Evaluation, Questionnaire, Malignant tumor, Mammary gland diseases, Sex steroid hormone

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0425811

    Code Inist : 002B20E02. Création : 10/04/1997.